31 – 40 of 43
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies
(
- Contribution to journal › Article
- 2018
-
Mark
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease : a cohort study
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
- 2017
-
Mark
Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)
(
- Contribution to journal › Article
-
Mark
18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Tau pathology distribution in Alzheimer's disease corresponds differentially to cognition-relevant functional brain networks
(
- Contribution to journal › Article
- 2016
-
Mark
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
(
- Contribution to journal › Article